Carbon monoxide (CO) poisoning is a common clinical acute poisoning type, characterized by acute onset and rapid progression. In severe cases, it can lead to coma, multiple organ failure, and even death. As a core treatment for carbon monoxide poisoning, hyperbaric oxygen chamber therapy, with its unique mechanism of action, can significantly improve the success rate of treatment and reduce the incidence of sequelae, occupying an irreplaceable position in clinical treatment. The following detailedly explains the therapeutic effect of hyperbaric oxygen chamber from the aspects of mechanism of action, core therapeutic value, scope of application and precautions.
I. Core Mechanism of Action: Targeting the Essence of Poisoning to Rapidly Eliminate Toxicity
The essence of carbon monoxide poisoning is that CO has an extremely strong affinity with human hemoglobin (Hb) (about 240 times that of oxygen with Hb), and the carboxyhemoglobin (COHb) formed after binding dissociates very slowly (only 1/3600 of the dissociation rate of oxyhemoglobin). This will cause Hb to lose its oxygen-carrying capacity, resulting in tissue hypoxia of the body. Especially the brain tissue and myocardium, which are extremely sensitive to hypoxia, will first experience functional damage. Hyperbaric oxygen chamber therapy fundamentally solves this pathological process through the dual effects of "hyperbaric environment + high-concentration oxygen":
1. Accelerating the Dissociation of Carboxyhemoglobin and Restoring the Oxygen-Carrying Function of Hemoglobin
The hyperbaric oxygen environment can significantly increase the concentration of physically dissolved oxygen in the blood (under normal pressure, about 0.3 mL of oxygen is dissolved in 100 mL of blood, which can be increased to more than 6 mL under 2.5 ATA hyperbaric oxygen), greatly increasing the partial pressure of blood oxygen. High blood oxygen partial pressure can competitively bind to Hb and accelerate the dissociation rate of COHb. Studies have shown that when inhaling air under normal pressure, the half-life of COHb is about 4 to 6 hours, while under 2 ATA hyperbaric oxygen environment, the half-life can be shortened to 20 to 30 minutes, which can quickly restore the oxygen-carrying capacity of Hb and relieve the state of tissue hypoxia.
2. Improving Tissue Hypoxia and Reversing Pathological Damage
Hyperbaric oxygen can not only improve the oxygen-carrying capacity of the blood, but also increase the diffusion distance of oxygen (under normal pressure, the diffusion radius of oxygen is about 30 μm, which can be increased to more than 100 μm under hyperbaric oxygen), enabling oxygen to penetrate into tissue cells more efficiently, especially brain tissue and myocardial cells that are sensitive to hypoxia. This effect can quickly correct cellular hypoxia, inhibit the damage processes such as free radical generation and lipid peroxidation caused by hypoxia, reduce secondary pathological changes such as cerebral edema and myocardial damage, and lower the mortality rate of critically ill patients.
3. Inhibiting the Inhibitory Effect of Carbon Monoxide on Cytochrome Oxidase
In addition to binding to Hb, CO can also bind to cytochrome oxidase in cells, inhibit the oxidative phosphorylation process of mitochondria, and block the energy metabolism of cells. Hyperbaric oxygen can competitively bind to cytochrome oxidase through high oxygen partial pressure, relieve the inhibition of this enzyme by CO, restore the energy synthesis function of cells, and avoid cell necrosis due to energy exhaustion.
II. Core Therapeutic Value: Improving Treatment Effect and Reducing the Risk of Sequelae
1. Significantly Reducing Mortality and Improving Prognosis of Critically Ill Patients
For patients with moderate to severe carbon monoxide poisoning (presenting with symptoms such as coma, convulsions, dyspnea, and hypotension), timely hyperbaric oxygen therapy can quickly correct severe tissue hypoxia, prevent the progression of the disease to multiple organ failure, and significantly reduce the mortality rate. Clinical data show that if patients with moderate to severe poisoning receive standardized hyperbaric oxygen therapy within 6 hours after poisoning, the mortality rate can be reduced by more than 50%.
2. Reducing the Occurrence of Delayed Encephalopathy
Delayed encephalopathy after carbon monoxide poisoning is the most common sequela, referring to the recurrence of neurological damage symptoms such as dementia, Parkinson's syndrome, hemiplegia, and mental disorders in patients after the relief of acute poisoning symptoms (latent period, usually 2 to 60 days). Its core inducement is cerebrovascular endothelial damage, microcirculatory disturbance and demyelination of brain tissue caused by acute hypoxia. Hyperbaric oxygen therapy can significantly reduce the incidence of delayed encephalopathy by improving cerebral microcirculation, repairing damaged cerebrovascular endothelium, and inhibiting neuronal apoptosis. Studies have shown that standardized hyperbaric oxygen therapy can reduce the incidence of delayed encephalopathy to less than 5%, and has a certain reversing effect on early neurological symptoms that have appeared.
3. Shortening the Course of Disease and Improving Rehabilitation Efficiency
Compared with conventional oxygen inhalation therapy, hyperbaric oxygen can relieve poisoning symptoms (such as headache, dizziness, nausea, confusion, etc.) more quickly, and shorten the coma time and hospital stay of patients. For patients with mild poisoning, hyperbaric oxygen therapy can quickly eliminate CO in the body and avoid recurrent symptoms; for patients with severe poisoning, it can gain time for subsequent nerve repair and organ function support treatment, and improve the overall rehabilitation efficiency.
III. Scope of Application: Covering All Types of Poisoning, Emphasizing Early Intervention
Hyperbaric oxygen chamber therapy is applicable to patients with various degrees of carbon monoxide poisoning, especially those with the following clear therapeutic indications:
Patients with moderate to severe poisoning: presenting with consciousness disturbance (coma, somnolence, confusion), convulsions, dyspnea, arrhythmia, abnormal blood pressure and other symptoms, or blood COHb concentration ＞20%;
Patients with mild poisoning but with high-risk factors: such as the elderly, infants and young children, pregnant women (CO can affect the fetus through the placenta, leading to fetal hypoxia), and patients with underlying diseases such as cardio-cerebrovascular diseases and diabetes;
Patients who need to prevent delayed encephalopathy after the relief of acute poisoning symptoms: especially those who have experienced transient coma, memory loss, limb numbness and other symptoms after poisoning;
Patients with carbon monoxide poisoning complicated with other organ injuries (such as acute lung injury, acute renal injury, etc.).